The September board changed twice before the next Monday arrived.
FDA approved Scholar Rock's apitegromab on September 11, more than two weeks ahead of its September 30 target. ISEMBYLD is now approved for adults and children age 2 and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment.
Telix resolved the remaining open question in an announcement dated September 14. FDA approved Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma. The approved use covers adults and pediatric patients age 1 month and older and differentiates recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations.
Pixclara now moves off the live board. The next fixed clock is UX111 on Saturday, followed by WINREVAIR on Monday. Six scheduled September decisions remain, with four concentrated between September 26 and September 30.
This week's distinction: the calendar tells us when FDA aimed to act; only a disclosed decision tells us what happened.
| Status / date | Sponsor / ticker | Event | Setup class | Main risk | PoA |
|---|---|---|---|---|---|
| Sat Sep 19* | Ultragenyx / RARE | UX111 / Sanfilippo syndrome type A | Resubmitted BLA; accelerated-approval request | CMC / facility remediation | 79% |
| Mon Sep 21 | Merck / MRK | WINREVAIR / HYPERION-based PAH label update | sBLA | Label scope / execution | 96% |
| Sat Sep 26* | Mirum (licensed from Incyte) / MIRM | zilurgisertib / FOP, ages 12+ | Priority Review NDA | Pivotal evidence / benefit-risk / label | 78% |
| Mon Sep 28 | Egetis (Stockholm-listed) | Emcitate / MCT8 deficiency | Priority Review NDA | Rare-disease evidence / U.S. label | 83% |
| Mon Sep 28 | Biofrontera / BFRI | Ameluz + RhodoLED / superficial basal cell carcinoma | sNDA; drug-device indication expansion | Treatment protocol / label | 85% |
| Wed Sep 30 | Bristol Myers Squibb / BMY | CAMZYOS / symptomatic obstructive HCM, ages 12–<18 | Priority Review sNDA | Pediatric label / safety monitoring | 91% |
Saturday targets: distinguish FDA action from the timing of the public announcement. PoAs are unchanged from the September 7 issue because no new application-specific evidence justified a revision.
Date and status sources: Ultragenyx, Merck Q4 and full-year 2025 earnings release, Mirum, Egetis March 27 NDA-acceptance release, Biofrontera February 11 filing-acceptance release, Bristol Myers Squibb.
SCHOLAR ROCK / ISEMBYLD — APPROVED SEP 11
FDA approved ISEMBYLD (apitegromab-mstn) for adults and children age 2 and older with SMA who are currently receiving an SMN2-targeted treatment. The approval resolves the prior fill-finish question: the application cleared after Scholar Rock removed the Catalent Indiana facility and proceeded with its alternate facility.
The label is combination-dependent rather than a stand-alone SMA indication. In the pivotal study, the approved 10 mg/kg dose improved motor function versus placebo on top of background SMN2 therapy. FDA also identified an increased fracture risk, including serious fractures. Scholar Rock said launch was underway and product would be available to ship within days. FDA decision, company announcement.
BAYER / HYRNUO — FIRST-LINE EXPANSION APPROVED SEP 9
FDA granted accelerated approval to HYRNUO (sevabertinib) for adults with locally advanced or metastatic non-squamous NSCLC whose tumors carry HER2 tyrosine-kinase-domain activating mutations, without a prior-systemic-therapy requirement.
Among 69 previously untreated patients in SOHO-01, the objective response rate was 75%. Of the responders, 73% had a response lasting at least six months and 38% at least 12 months. The approval expands an existing accelerated-approval indication into an earlier treatment setting. Its evidence base remains the single-arm SOHO-01 response analysis. FDA decision.
TELIX / PIXCLARA — APPROVAL ANNOUNCED SEP 14
Telix announced that FDA approved Pixclara (floretyrosine F 18), an intravenous FET-PET imaging drug for glioma. The indication covers adults and pediatric patients age 1 month and older and is specific: use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations.
The company announcement arrived after the September 11 goal date and closes the unresolved status carried in the Sunday draft. Telix calls Pixclara the first FDA-approved FET-PET imaging drug for glioma and the only FDA-approved radiopharmaceutical imaging drug for glioma. The next read shifts from approval probability to access, radiopharmacy distribution and clinical adoption.
PHARMING / JOENJA — PEDIATRIC EXPANSION APPROVED SEP 11
FDA expanded JOENJA (leniolisib) to children age 4–11 with activated PI3K-delta syndrome who weigh at least 27 kg. The drug was already approved for patients age 12 and older; the new label uses weight-based dosing in the younger group. FDA decision, company announcement.
The clean read: The prior CRL centered on CMC information and manufacturing-inspection observations. Ultragenyx reported that FDA viewed the neurodevelopmental data as robust and the biomarker evidence as supportive. That makes this principally a manufacturing-repair setup, while leaving the full application's approvability for FDA to decide. Prior CRL disclosure.
The clean read: WINREVAIR is already approved in adult pulmonary arterial hypertension. FDA updated the U.S. label in October 2025 using ZENITH, specifying the clinical-worsening events covered—PAH hospitalization, lung transplantation and death. The September 21 application would be a second label update in under a year, this time using HYPERION in patients diagnosed within the prior year who remained at intermediate or high risk on background therapy.
HYPERION was stopped early after the program's evidence made continued placebo assignment untenable. In the final analysis, WINREVAIR reduced the risk of clinical-worsening events by 76% versus placebo. That matches ZENITH's headline reduction, but the trials asked different questions: ZENITH studied high-risk WHO functional class III or IV adults and counted death, lung transplant or PAH hospitalization of at least 24 hours; HYPERION studied recently diagnosed functional class II or III adults at intermediate or high risk and used a broader composite that also included atrial septostomy and PAH deterioration. FDA is reviewing how the HYPERION evidence should change the existing label. October 2025 ZENITH label update, HYPERION results.
September 11 produced both sides of the timing problem. ISEMBYLD was approved early relative to its September 30 target. Pixclara reached its printed goal date without a public outcome located by Sunday, and Telix announced the approval on September 14.
A PDUFA date is FDA's target for completing a review. Public disclosure can arrive before or after the printed date. Keep the event open until a primary source establishes the outcome, then move it to resolved.
The date starts the verification check. It does not replace it.
Editorial risk map—not a forecast of undisclosed FDA findings.
| Name | First question after an adverse action |
|---|---|
| RARE / UX111 | Were the CMC and facility corrective actions sufficient? |
| MRK / WINREVAIR | Was the requested HYPERION-based label change supported as filed? |
| Mirum (licensed from Incyte) | Did the FOP evidence support the proposed ages-12+ indication? |
| Egetis | What limitation did FDA identify in the evidence or proposed U.S. label? |
| BFRI | Did the sBCC evidence and drug-device treatment protocol support the expansion? |
| BMY / CAMZYOS | Did adolescent benefit-risk and safety monitoring support the proposed label? |
RESOLVED EVENTS
NOT AN FDA-ASSIGNED CLOCK
Latest resolution: Pixclara is approved and leaves the live board. The announcement confirms the age floor, the diagnostic role and the need to use it with other evaluations.
First fixed live target: UX111 on Saturday, September 19. Keep its manufacturing repair separate from Ultragenyx's recent Angelman-program setback.
Next label event: WINREVAIR on Monday, September 21. The final label matters more than the word “approved.”
Late-month concentration: Four scheduled decisions in five days—zilurgisertib, Emcitate, Ameluz and CAMZYOS. ISEMBYLD's early approval reduced that cluster by one.
What last week answered: An alternate fill-finish path was sufficient for ISEMBYLD's U.S. approval. HYRNUO moved into the first-line setting under accelerated approval. Pixclara cleared review with a defined diagnostic claim for patients age 1 month and older.
For every FDA “yes,” read which patients, which claim, which operating constraint and which remaining obligation the decision covers.
Follow the FDA decision board. Forward this issue to someone tracking September's dates without tracking the questions behind them.
Informational only. Not investment advice. Biotech investing carries the risk of total loss.